Normal cells have a series of molecular controls that prevents them from proliferating in the absence of essential environmental cues. These environmental cues include the presence of mitogenic growth factors and a suitable extracellular matrix (ECM). Cancer cells have lost these controls and thus can divide in the absence of these extracellular signals. We and others have examined how mitogenic growth factors and the ECM cooperate to regulate a cell's decision to proliferate and which of these controls are typically lost in cancer cells. The results of these studies have also provided insights into the functions of oncogenes and transforming cytokines.
because these enzymes are now believed to be responsible for mediating progression through the growth-regulatory portion of the cell cycle. We found that each of the cell cycle events required for cell cycle progression through G 1 phase (eg , induction of cyclin D1/PRAD1, phosphorylation of the retinoblastoma protein [pRB], and induction of cyclin A) requires coordinated signaling by growth factors and the ECM. Overall, these studies have allowed us to develop a model showing how the extracellular environment controls proliferation in normal cells. [1] [2] [3] We then asked if this information might help to explain some long-standing questions regarding the mechanisms by which certain cytokines (eg , transforming growth factor [TGF]-beta) or oncogenes (eg , ras) deregulate cell growth.
TGF-beta was originally identified and purified by its ability to induce a transformed phenotype (anchorage-independent growth) in normal cells. However, subsequent studies showed that this original effect was restricted to a few isolated cell lines (eg , NRK cells) and that TGF-beta is typically an inhibitor of cell growth. We have hypothesized that the transforming effect of TGF-beta in these isolated cell lines might be providing an important clue about "multistep progression" to cancer. Specifically, we reasoned that cells transformed by TGF-beta must have undergone a selective mutation that, while nontransforming in itself, renders them susceptible to transformation by TGF-beta. We therefore looked at the regulation of the G 1 cyclins in NRK cells and found that these cells had lost their ECM requirement for induction of cyclin D1. In fact, loss of anchoragedependent cyclin D1 expression is causal for transformation by TGF-beta because when we force cyclin D1 expression in nontransformed cells, they become sensitive to transformation by TGF-beta.
These studies have potential implications for cell transformation by the oncogene ras. One of the critical targets of activated ras is a cytoplasmic kinase called mitogen-activated protein (MAP) kinase. When ras becomes activated (either in response to growth factors and the ECM in normal cells or by point mutation in cancer cells), MAP kinase becomes activated and induces the expression of cyclin D1. 4 If cyclin D1 is abnormally expressed, then pRB can be abnormally phosphorylated and G 1 phase becomes deregulated. Indeed, we and others have shown that constitutive activation of MAP kinase or constitutive expression of cyclin D1 induces, at least in part, the phenotype seen in ras-transformed cells.
In summary, normal cells use growth factors and the ECM to control the activation of ras and MAP kinase and hence the expression of cyclin D1. Mutations that result in oncogenic ras contribute to cell transformation, in part because they deregulate the activation of MAP kinase and expression of cyclin D1. Full-cell transformation requires the action of a second oncogene (eg , myc) or cytokine (eg , TGF-beta) in order to complement the cyclin D1 signal and allow for maximal pRB phosphorylation and cell cycle progression into S phase. Presumably, this complementary signal will ultimately affect the cyclin -dependent kinase machinery.
